Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

FDA Approves Exelixis’s Kidney Cancer Drug Cabometyx

April 25, 2016, 9:44 PM

The FDA April 25 approved Exelixis Inc.'s Cabometyx (cabozantinib) for treating patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

RCC is the most common form of kidney cancer in adults, Exelixis said in a press release. Cabometyx, the tablet formulation of cabozantinib, will be available in 20-, 40- or 60-milligram doses. The recommended dose is 60 milligrams orally, once daily, the South San Francisco, Calif.-based company said.

“With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer while ...